Antigenicity of putative phospholipid membrane-binding residues in factor VIII

Blood

Volumn 97, Issue 1, 2001, Pages 169-174

  Barrow, Rachel T ^b   Healey, John F ^b   Jacquemin, Marc G ^b   Saint Remy, Jean Marie R ^b   Lollar, Pete ^a  

^a EMORY UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ANTIGENICITY; ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD CLOTTING; HUMAN; NONHUMAN; PHOSPHOLIPID MEMBRANE; PRIORITY JOURNAL;

EID: 0035169521     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.1.169     Document Type: Article

References (32)

1. Factor VIII inhibitors: Structure and function in autoantibody and hemophilia A patients
2. The inhibitory antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with fVIII autoantibodies
3. Reduction of the antigenicity of factor VIII toward complex inhibitory plasmas using multiply substituted hybrid human/porcine factor VIII molecules
4. Molecular basis of factor-VIII inhibition by human antibodies - Antibodies that bind to the factor-VIII light chain prevent the interaction of factor-VIII with phospholipid
5. Binding to phospholipid protects factor VIII from inactivation by human antibodies
6. A role for the C2 domain of factor binding to von Willebrand factor
7. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor
8. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor
9. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and human antibody is a novel mechanism for factor VIII inhibition
10. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes
11. Structure of the C2 domain of human factor VIII at 1.5 Å resolution
12. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII
13. Mechanism and kinetics of factor VIII inactivation: Study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor
14. A soluble recombinant factor VIII fragment containing the A2 domain binds to some human anti-factor VIII antibodies that are not detected by immunoblotting
15. Expression of the amino-terminal half-molecule of human serum transferrin in cultured cells and characterization of the recombinant protein
16. Novel forms of B-domain-deleted recombinant factor VIII molecules: Construction and biochemical characterization
17. Gene splicing by ovelap extension
18. The clinical and laboratory diagnosis at hemorrhagic disorders
19. A more uniform measurement at factor VIII inhibitors
20. Elimination of a major inhibitor epitope in factor VIII
21. Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments
22. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine
23. Crystal structures of the membrane-binding C2 domain of human coagulation factor V
24. Identification of functionally important amino acid residues within the C2-domain at human factor V using alanine-scanning mutagenesis
25. Localization of functionally important epitopes within the second C-type domain of coagulation factor V using recombinant chimeras
26. Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations
27. C2 domain restricted epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors
28. Structure of human factor VIII
29. Molecular cloning at a cDNA encoding human antihaemophilic factor
30. The cDNA and derived amino acid sequence of porcine factor VIII
31. Sequence of the murine factor VIII cDNA
32. The canine factor VIII cDNA and 5′ flanking sequence